New molecule interferes with heat shock protein activities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival.

Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival.

The Philadelphia-based group showed that the inhibitor, called PES, interacted with HSP70 by blocking its stress-relieving functions. It also induces HSP70-dependent cell death by disrupting the cell’s ability to remove damaged components (Mol Cell 9:15-27, 2009).

The research was conducted by Donna George, PhD, associate professor of genetics, and Julie Leu, PhD, assistant professor of genetics, both at the University of Pennsylvania School of Medicine, in collaboration with the lab of Maureen Murphy, PhD, at Fox Chase Cancer Center.

PES seems to be specifically targeting HSP70, according to Dr. George. While studies in humans are still needed, “the exciting part is that this is a pathway and a protein target that clearly is important for cancer cells,” she said.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content